Budget Amount *help |
¥3,640,000 (Direct Cost: ¥2,800,000、Indirect Cost: ¥840,000)
Fiscal Year 2020: ¥1,040,000 (Direct Cost: ¥800,000、Indirect Cost: ¥240,000)
Fiscal Year 2019: ¥780,000 (Direct Cost: ¥600,000、Indirect Cost: ¥180,000)
Fiscal Year 2018: ¥780,000 (Direct Cost: ¥600,000、Indirect Cost: ¥180,000)
Fiscal Year 2017: ¥1,040,000 (Direct Cost: ¥800,000、Indirect Cost: ¥240,000)
|
Outline of Final Research Achievements |
We surveyed the serotypes and antimicrobial susceptibility profile of 44 S. pneumoniae isolates obtained from the middle ear fluid of children with acute otitis media from March 2017 to February 2018, in order to research serotype replacement after the 13-valent pneumococcal conjugate vaccine (PCV13) introduction in Japan. The most prevalent serotypes found were serotype 15A (15.9%), and serotype 23B (11.4%). 7-valent pneumococcal conjugate vaccine (PCV7) types accounted for 0% of all strains, while 9.1% were PCV13 types. Serotype 15A strains were 100% non-susceptible to penicillin G. Finally, the high prevalence of non-susceptible serotype 15A highlights the serotype 15A should be noted as a cause of intractable acute otitis media in children.
|